explore -WSS

explore

author：explore 2025-09-28 20:44:35 - browse：816

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Amid AI frenzy, a top HHS official's quest to create safeguards

Wikipedia

WSS

Health and fitness trackers are measuring the wrong things

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

RaDonda Vaught links Vanderbilt hospital issues to patient death

New England Journal of Medicine addresses racist history, slavery

Boston's new lab space is opening empty

Boston's new lab space is opening empty

entertainment

explore

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

Generative AI mines health records to identify patients’ social needs

Guidelines to prevent youth baseball injuries need more muscle

How to save health care price transparency rules

Activists slam private health insurers over coverage restrictions

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Hepatitis C has a cure — but many Americans still lack access to it

Risky weight loss products often used by teens globally, per study

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The SUPPORT Act is critical to fighting the opioid crisis

focus

Medicare coverage of Wegovy, once blocked, now looks possible

New menopause drug shows promise in relief for hot flashes

JPM 2024: Nvidia claims we're in biological revolution. Are we?

JPM 2024: Verve Therapeutics looks to mainstream genome editing

WuXi out of biotech trade group, U.S. and China relations to blame

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Wikipedia

entertainment

Wikipedia

hotspot